Nanomedicines as cancer therapeutics: Current status

Current Cancer Drug Targets

Volumn 13, Issue 4, 2013, Pages 362-378

  Akhter, Sohail ^a   Ahmad, Iqbal ^b   Ahmad, Mohammad Zaki ^c   Ramazani, Farshad ^a   Singh, Anjali ^b   Rahman, Ziyaur ^d   Ahmad, Farhan Jalees ^b   Storm, Gert ^a,e   Kok, Robbert J ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b HAMDARD UNIVERSITY   (India)

^c NAJRAN UNIVERSITY   (Saudi Arabia)

^d TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^e UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

Cancer nanomedicine; Multi drug resistance; Nanotechnology; Nanotoxicity; Regulatory; Theranostics

Indexed keywords

APTAMER; BEVACIZUMAB; BRENTUXIMAB VEDOTIN; CAMPTOTHECIN; CARBON NANOTUBE; CISPLATIN; DENDRIMER; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FAS ANTIGEN; FERUCARBOTRAN; FOLATE RECEPTOR; GEMTUZUMAB OZOGAMICIN; GOLD NANOPARTICLE; GONADORELIN; INTEGRIN; LIPOSOME; MAGNETIC NANOPARTICLE; MONOCLONAL ANTIBODY; NANOCARRIER; NANOPARTICLE; NIOSOME; PACLITAXEL; PERTUZUMAB; QUANTUM DOT; SOLID LIPID NANOPARTICLE; SUPERPARAMAGNETIC IRON OXIDE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; TYROSINE KINASE RECEPTOR; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BREAST METASTASIS; CANCER THERAPY; CYTOTOXICITY; DRUG TARGETING; HODGKIN DISEASE; HUMAN; KAPOSI SARCOMA; MULTIDRUG RESISTANCE; NANOMEDICINE; NONHUMAN; ONCOLOGY; OVARY CANCER; OXIDATIVE STRESS;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; NANOPARTICLES; NEOPLASMS; PHARMACEUTICAL PREPARATIONS;

EID: 84878637915     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009611313040002     Document Type: Article

References (163)

1. Rahman, M.; Ahmad, M.Z.; Kazmi, I.; Akhter, S.; Afzal, M.; Gupta, G.; Ahmed, F.J.; Anwar, F. Advancement in multifunctional nanoparticles for the effective treatment of cancer. Expert Opin. Drug Deliv. 2012, 9 (4), 367-381.
2. Youns, M.; Hoheisel, J.D.; Efferth, T. Therapeutic and diagnostic applications of nanoparticles. Curr. Drug Targets 2011, 12 (3), 357-365.
3. Alexis, F.; Rhee, J.W.; Richie, J.P.; Radovic-Moreno, A.F.; Langer, R.; Farokhzad, O.C. New frontiers in nanotechnology for cancer treatment. Urol. Oncol. 2008, 26 (1), 74-85.
4. Jain, K.K. Advances in the field of nanooncology. BMC Med. 2010, 13 (8), 83-91.
5. Jain, R.K. Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function. J. Control. Release 2001, 74(1-3), 7-25.
6. Gao, Z.; Zhang, L.; Sun, Y. Nanotechnology applied to overcome tumor drug resistance. J. Control. Release 2012, 162(1), 45-55.
7. Liu, Y.; Lu, W. Recent advances in brain tumor-targeted nano-drug delivery systems. Expert Opin. Drug Deliv. 2012, 9(6), 671-686.
8. Perou, C.M.; Sorlie, T.; Eisen, M.B.; van de Rijn, M.; Jeffrey, S.S.; Rees C.A.; Pollack, J.R.; Ross, D.T.; Johnsen, H.; Akslen, L.A.; Fluge, O.; Pergamenschikov, A.; Williams, C.; Zhu, X.S.; Lønning, P.E.; Børresen-Dale, A.; Brown, O.P.; Botstein, D. Molecular portraits of human breasts tumors. Nature 2000, 406 (6797), 747-752.
9. Dhanasekaran, S.M.; Barrette, T.R.; Ghosh, D.; Shah, R.; Varambally, S.; Kurachi, K.; Pienta, K.J.; Rubin, M.A.; Chinnaiyan, A.M. Delineation of prognostic biomarkers in prostate cancer. Nature 2001, 412 (6849), 822-826.
10. Shom, G.; Dan, G.; Duda, Lei. Xu.; Lance, L.; Munn, Yves. Boucher.; Dai, F.; Rakesh, K. J. Normalization of the vasculature for treatment of cancer and other diseases. Physiol. Rev. 2011, 91 (3), 1071-1121.
11. Rapisarda, A.; Melillo, G. Role of the VEGF/VEGFR axis in cancer biology and therapy. Adv. Cancer Res. 2012, 114 (2), 237-267.
12. Davis, F.F. The origin of pegnology. Adv. Drug Deliv. Rev. 2002, 54 (19), 457-458.
13. Moghimi, S.M.; Hunter, A.C. Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. Trends Biotechnol. 2000, 18 (10), 412-420.
14. Park, E.K.; Lee, S.B.; Lee, Y.M. Preparation and characterization of methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) amphiphilic block copolymeric nanospheres for tumor-specific folate-mediated targeting of anticancer drugs. Biomaterials 2005, 26 (9), 1053-1061.
15. Larsen, A.K.; Escargueil, A.E.; Skladanowski, A. Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol. Therapeutics. 2000, 85 (3), 217-229.
16. Links, M.; Brown, R. Clinical relevance of the molecular mechanisms of resistance to anticancer drugs. Expert Rev. Mol. Med. 1999, 19(7), 1-21.
17. Krishna, R.; Mayer, L.D. Multidrug resistance (MDR) in cancer mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 2000, 11(4), 265-283.
18. Vauthier, C.; Dubernet, C.; Chauvierre, C.; Brigger, I.; Couvreur, P. Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. J. Control. Release 2003, 93 (2), 151-160.
19. Deverdiere, A.C.; Dubernet, C.; Nemati, F.; Soma, E.; Appel, M.; J. Fert, J.; Bernard, S.; Puisieux, F.; Couvreur, P. Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action. Brit. J. Cancer 1997, 76 (2), 198-205.
20. Tsuruo, T. Molecular cancer therapeutics: recent progress and targets in drug resistance. Intern. Med. 2003, 42 (3), 237-243.
21. Blagosklonny, M.V. Targeting cancer cells by exploiting their resistance. Trends Mol. Med. 2003, 9 (7), 307-312.
22. Antony, A.C. The biological chemistry of folate receptors. J. Am. Soc. Hematol. 1992, 79 (21), 2807-2820.
23. Lu, Y.; Low, P.S. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv. Drug Deliv. Rev. 2002, 54 (5), 675-693.
24. Sudimack, J.B.A.; Lee, R.J. Targeted drug delivery via the folate receptor. Adv. Drug Deliv. Rev. 2000, 41 (2), 147-162.
25. Minko, T.; Dharap, S.S.; Pakunlu, R.I.; Wang, Y. Molecular targeting of drug delivery systems to cancer. Curr. Drug Targets 2004, 5 (4), 389-406.
26. Rege, B.D.; Kao, J.P.Y.; Polli, J.E. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur. J. Pharm. Sci. 2002, 16 (27), 237-246.
27. Pan J.; Feng, S.S. Targeted delivery of paclitaxel using folatedecorated poly (lactide) evitamin E TPGS nanoparticles. Biomaterials 2008, 29 (17), 2663-2672.
28. Oyewumi, M.O.; Mumper, R.J. Influence of formulation parameters on gadolinium entrapment and tumor cell uptake using folate-coated nanoparticles. Int. J. Pharmaceutics. 2003, 251 (1-2), 85-97.
29. Mehren, M.V.; Adams, G.P; Weiner, L.M. Monoclonal antibody therapy for cancer. Annu. Rev. Med. 2003, 54, 343-369.
30. Kohler, G.; Milstein, C. Continuous culture of fused cell secreting antibody of predefined specificity. Nature 1975, 256, 495-497.
31. Gu, F.X.; Karnik, R.; Wang, A.Z.; Alexis, F.; Levy-Nissenbaum, E.; Hong, S.; Langer, R. S.; Farokhzad, O.C. Targeted nanoparticles for cancer therapy. Nano Today 2007, 2, 14-21.
32. Kocbek, P.; Obermajer, N.; Cegnar, M.; Kos, J.; Kristl, J. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J. Control. Release 2007, 120, 18-26.
33. Steinhauser, I.; Spankuch, B.; Strebhardt, K.; Langer, K. Trastuzumab modified nanoparticles: optimisation of preparation and uptake in cancer cells. Biomaterials 2006, 27, 4975-4983.
34. Sievers, E.L.; Larson, R.A.; Stadtmauer, E.A.; Estey, E. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33- positive acute myeloid leukemia in first relapse. J. Clin. Oncol. 2001, 19, 3244-3254.
35. Sievers, E.L.; Senter, P.D. Antibody-Drug Conjugates in Cancer Therapy. Annu Rev Med. 2012, DOI: 10.1146/annurev-med-050311-201823.
36. Alley, S.C.; Okeley, N.M.; Senter, P.D. Antibody-drug conjugates: targeted drug delivery for cancer. Curr. Opin. Chem. Biol. 2010, 14 (4), 529-537.
37. Hurvitz, S.A.; Kakkar, R. The potential for trastuzumab emtansine in human epidermal growth factor receptor 2 positive metastatic breast cancer: latest evidence and ongoing studies. Ther. Adv. Med. Oncol. 2012, 4 (5), 235-245.
38. Jung, G.; Grosse-Hovest, L.; Krammer, P.H.; Rammensee, H.G. Target cell-restricted triggering of the CD95 (APO-1/Fas) death receptor with bispecific antibody fragments. Cancer Res. 2001, 61 (5), 1846-1848.
39. McCarron, P.A.; Marouf, W.M.; Quinn, D.J.; Fay, F.; Burden, R.E.; Olwill, S.A.; Scott, C.J. Antibody targeting of camptothecinloaded PLGA nanoparticles to tumor cells. Bioconjugate Chem. 2008, 19 (8), 1561-1569.
40. Huh, Y.M.; Jun, Y.W.; Song, H.T.; Kim, S.; Choi, J.S.; Lee, J.H.; Yoon, S.; Kim, K.S.; Shin, J.S.; Suh, J.S.; Cheon, J. In vivo magnetic resonance detection of cancer by using multifunctional magnetic nanocrystals. J. Am. Chem. Soc. 2005, 127, 12387-12391.
41. Akira, I.; Yuko, K.; Hiroyuki, H.; Hiroyuki, K.; Atsushi; Yuji, W.; Takeshi, K. Magnetite nanoparticle-loaded anti-HER2 immunoliposome for combination of antibody therapy with hyperthermia. Cancer Lett. 2004, 212, 167-175.
42. Chen, W.; Bardhan, R.; Bartels, M.; Perez-Torres, C.; Pautler, R.G.; Halas, N.J.; Joshi, A. A molecularly targeted theranostic probe for ovarian cancer. Mol. Cancer Ther. 2010, 9 (4), 1028-1038.
43. Day, E.S.; Bickford, L.R.; Slater, J.H.; Riggall, N.S.; Drezek, R.A.; West, J.L. Antibody-conjugated gold-gold sulfide nanoparticles as multifunctional agents for imaging and therapy of breast cancer. Int. J. Nanomed. 2010, 9, 445-454.
44. Lee, J.F.; Hesselberth, J.R.; Meyers, L.A.; Ellington, A.D. Aptamer database. Nucleic Acids Res. 2004, 32, 95-100.
45. Wang, J.; Li, G. Aptamers against cell surface receptors: selection, modification and application. Curr. Med. Chem. 2011, 18 (27), 4107-4116.
46. Gold, L.; Tuerk, C. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249, 505-510.
47. Levy-Nissenbaum, E.; Radovic-Moreno, A.F.; Wang, A.Z.; Langer, R.; Farokhzad, O.C. Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol. 2008, 24, 442-449.
48. Mukerjee, A.; Ranjan, A.P.; Vishwanatha, J.K. Combinatorial nanoparticles for cancer diagnosis and therapy. Curr. Med. Chem. 2012, 19 (22), 3714-3721.
49. Farokhzad, O.C.; Jon, S.; Khademhosseini, A.; Tran, T.T.; Lavan, D.A.; Langer, R. Nanoparticle aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res. 2004, 64, 7668-7672.
50. Yang, L.; Zhang, X.; Ye, M.; Jiang, J.; Yang, R.; Fu, T.; Chen, Y.; Wang, K.; Liu, C.; Tan, W. Aptamer-conjugated nanomaterials and their applications. Adv. Drug Deliver. Rev. 2011, 63 (14-15), 1361-1370.
51. Chong, V. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors. Ophthalmologica 2012, 227 (1), 2-10.
52. Mousa, S.A. Anti-integrin as novel drug-discovery targets: potential therapeutic and diagnostic implications. Curr. Opin. Chem. Biol. 2002, 6, 534-541.
53. Danhier, F.; Le Breton, A.; Préat, V. RGD-based strategies to target alpha (v) beta(3) integrin in cancer therapy and diagnosis. Mol. Pharmaceutics 2012, 9 (11), 2961-2973.
54. Dufes, C.; Olivier, J.; Gaillard, F.; Gaillard, A.; Couet, W.J. Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats. Int. J. Pharmaceutics 2003, 255, 87-97.
55. Wernig, K.; Griesbacher, M.; Andreae, F.; Hajos, F.; Wagner, J.; Mosgoeller, W.; Zimmer A. Depot formulation of vasoactive intestinal peptide by protamine-based biodegradable nanoparticles. J. Control. Release 2008, 130, 192-198.
56. Torchilin, V.P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 2007, 9, 128-147.
57. Mezo, G.; Manea, M. Receptor-mediated tumor targeting based on peptide hormones. Expert Opin. Drug Deliv. 2010, 7 (1), 79-96.
58. Dharap, S.S.; Wang, Y.; Chandna, P.; Khandare, J.J.; Qiu, B.; Gunaseelan, S.; Sinko, P.J.; Stein, S.; Farmanfarmaian, A.; Minko, T. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc. Natl. Acad. Sci. USA 2005, 102 (36), 12962-12967.
59. Oussorena, C.; Elingb, W.M.C.; Crommelin, D.J.A. The influence of the route of administration and liposome composition on the potential of liposomes to protect tissue against local toxicity of two antitumor drugs. Biochim. Biophys. Acta. 1998, 1369, 159-172.
60. Coimbra, M.; Crielaard, B.J.; Storm, G.; Schiffelers, R.M. Critical factors in the development of tumor-targeted anti-inflammatory nanomedicines. J. Control. Release 2012, 160 (2), 232-238.
61. Schiffelers, R.M.; Koning, G.A.; ten Hagen, T.L.; Fens, M.H.; Schraa, A.J.; Janssen, A.P.; Kok, R.J.; Molema, G.; Storm, G. Antitumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J. Control. Release 2003, 91 (1-2), 115-122.
62. Gabizon, A.; Shmeeda, H.; Horowitz, A.T.; Zalipsky, S. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv. Drug. Deliver. Rev. 2004, 56 (8), 1177-1192.
63. Yokoe, J.; Sakuragi, S.; Yamamoto, K.; Teragaki, T.; Ogawara, K.; Higaki, K.; Katayama, N.; Kai, T.; Sato, M.; Kimura, T. Albuminconjugated PEG liposome enhances tumor distribution of liposomal doxorubicin in rats. Int. J. Pharmaceutics 2008, 353 (1, 2), 28-34.
64. Riganti, C.; Voena, C.; Kopecka, J.; Corsetto, P.A.; Montorfano, G.; Enrico, E.; Costamagna, C.; Rizzo, A.M.; Ghigo, D. Bosia. A Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells. Mol. Pharmaceutics. 2011, 8 (3), 683-700.
65. Akhter, S.; Kushwaha, S.; Warsi, M.H.; Anwar, M.; Ahmad, M.Z.; Ahmad, I.; Talegaonkar, S.; Khan, Z.I.; Khar, R.K.; Ahmad, F.J. Development and evaluation of nanosized niosomal dispersion for oral delivery of Ganciclovir. Drug Dev. Ind. Pharm. 2012, 38, 84-92.
66. Akhter, S.; Talegaonkar, S.; Khan, Z.I.; Jain, G.K.; Khar, R.K.; Ahmad, F.J. Assessment of ocular pharmacokinetics and safety of Ganciclovir loaded nanoformulations. J. Biomed. Nanotechnol. 2011, 7, 144-145.
67. Hong, M.; Zhu, S.; Jiang, Y.; Tang, G.; Pei, Y. Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin. J. Control. Release 2009, 133 (2), 96-102.
68. Kataoka, K.; Matsumoto, T.; Yokoyama, M.; Okano, T.; Sakurai, Y.; Fukushima, S.; Okamoto, K.; Kwon, G.S. Doxorubicin-loaded poly(ethylene glycol)-poly(beta-benzyl-l-aspartate) copolymer micelles: their pharmaceutical characteristics and biological significance. J. Control. Release 2000, 64 (1-3), 143-153.
69. Kwon, G.; Naito, M.; Yokoyama, M.; Okano, T.; Sakurai, Y.; Kataoka, K. Block copolymer micelles for drug delivery: loading and release of doxorubicin. J. Control. Release 1997, 48 (2, 3), 195-201.
70. Kedar, U.; Phutane, P.; Shidhaye, S. Advances in polymeric micelles for drug delivery and tumor targeting. Nanomedicine 2010, 6, 714-729.
71. Rapoport, N. Physical stimuli-responsive polymeric micelles for anti-cancer drug delivery. Progr. Polym. Sci. 2007, 32, 962-990.
72. Mu, L.; Feng, S.S. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol®): PLGA nanoparticles containing vitamin E TPGS. J. Control. Release 2003, 86, 33-48.
73. Gryparis, E.C.; Hatziapostolou, M.; Papadimitriou, E. Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells. Eur. J. Pharm. Biopharm. 2007, 67, 1-8.
74. Li, N.; Yang, X.; Zhai, G.; Li, L. Multifunctional pluronic/poly(ethylenimine) nanoparticles for anticancer drug J. Colloid Interf. Sci. 2010, 350, 117-125.
75. Mo, Y.; Lim, L.Y. Preparation and in vitro anticancer activity of wheat germ agglutinin (WGA)-conjugated PLGA nanoparticles loaded with paclitaxel and isopropyl myristate. J. Control. Release 2005, 107, 30-42.
76. Subedi, R.K.; Kang, K.W.; Choi, H.K. Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin. Eur. J. Pharm. Sci. 2009, 37 (3-4), 508-513.
77. De, M.; Ghosh, P.S.; Rotello, V.M. Applications of Nanoparticles in Biology. Adv. Mater. 2008, 20 (22), 4225-4241.
78. Mukherjee, P.; Bhattacharya, R.; Mukhopadhyay, D. Gold nanoparticles bearing functional anti-cancer drug and antiangiogenic agent: a "2 in 1" system with potential application in cancer therapeutics. J. Biomed. Nanotechnol. 2005, 1 (2), 224-228.
79. Mukherjee, P.; Bhattacharya, R.; Wang, P.; Basu, S.; Nagy, J.A.; Atala, A.; Mukhopadhyay, D.; Soker, S. Antiangiogenic properties of gold nanoparticles. Clin. Cancer Res. 2005, 11 (9), 3530-3534.
80. Curley, S.A.; Cherukuri, P.; Briggs, K.; Patra, C.R.; Upton, M.; Dolson, E.; Mukherjee, P. Noninvasive radiofrequency fieldinduced hyperthermic cytotoxicity in humancancer cells using cetuximab-targeted gold nanoparticles. J. Exp. Ther. Oncol. 2008, 7 (4), 313-326.
81. Patra, C.R.; Bhattacharya, R.; Mukhopadhyay, D.; Mukherjee, P. Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Adv. Drug Deliver. Rev. 2010, 62 (3), 346-361.
82. Ghosh, P.; Han, G.; De, M.; Kim, C.K.; Rotello, V.M. Gold nanoparticles in delivery applications. Adv. Drug Deliver. Rev. 2008, 60 (11), 1307-1315.
83. Kim, C.K.; Ghosh, P.; Rotello, V.M. Multimodal drug delivery using gold nanoparticles. Nanoscale 2009, 1 (1), 61-67.
84. Choi, C.H.; Alabi, C.A.; Webster, P.; Davis, M.E. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc. Natl. Acad. Sci. USA 2010, 107 (3), 1235-1240.
85. Shen, Q.; Wang, X.; Fu, D. The amplification effect of functionalized gold nanoparticles on the binding of anticancer drug dacarbazine to DNA and DNA bases. Appl. Surf. Sci. 2008, 255 (2), 577-580.
86. Cherukuri, P.; Glazer, E.S.; Curley, S.A. Targeted hyperthermia using metal nanoparticles. Adv. Drug. Deliver. Rev. 2010, 62 (3), 339-345.
87. Akhter, S.; Ahmad, M.Z, Ahmad, I.; Singh, A.; Anwar, M.; Ahmad, F J.; Khar, R.K. Cancer targeted metallic nanoparticle: Targeting overview, recent advancement and toxicity concern. Curr. Pharm. Des 2011, 17 (18), 1834-1850.
88. Ahmad, M.Z.; Akhter, S.; Jain, G.K.; Rahman, M.; Pathan, S.A.; Ahmad, F.J.; Khar, R.K. Metallic nanoparticles: technology overview & drug delivery applications in oncology. Expert Opin. Drug Deliv. 2010, 7 (8), 927-942.
89. Pankhurst, Q.A.; Connolly, J.; Jones, S.K.; Dobson, J. Applications of magnetic nanoparticles in biomedicine. J. Phys. D: Appl. Phys. 2003, 36 (13), R167.
90. Jain, T.K.; Morales, M.A.; Sahoo, S.K.; Leslie-Pelecky, D.L.; Labhasetwar, V. Iron Oxide Nanoparticles for Sustained Delivery of Anticancer Agents. Mol. Pharmaceutics. 2005, 2 (3), 194-205.
91. Yallapu, M.M.; Othman, S.F.; Curtis, E.T.; Gupta, B.K.; Jaggi, M.; Chauhan, S.C. Multi-functional magnetic nanoparticles for magnetic resonance imaging and cancer therapy. Biomaterials 2011, 32 (7), 1890-1805.
92. Maeng, J.H.; Lee, D.H.; Jung, K.H; Bae, Y.H.; Park, I.S.; Jeong, S.; Jeon, Y.S.; Shim, C.K.; Kim, W.; Kim, J.; Lee, J.; Lee, Y.M.; Kim, J.H.; Kim, W.H.; Hong, S.S. Multifunctional doxorubicin loaded superparamagnetic iron oxide nanoparticles for chemotherapy and magnetic resonance imaging in liver cancer. Biomaterials 2010, 31, 4995-5006.
93. Zhuo, R.X.; Du, B.; Lu, Z. In vitro release of 5-fluorouracil with cyclic core dendritic polymer. J. Control. Release 1999, 57 (3), 249-257.
94. Gardikis, K.; Hatziantoniou, S.; Signorellib, M. Thermodynamic and structural characterization of Liposomal-Locked in-Dendrimers as drug carriers. Colloid Surface B 2010, 81 (1), 11-9.
95. Iijima, S. Helical microtubules of graphitic carbon. Nature 1991, 354 (6348), 56-58.
96. Sinha, N.; Yeow, J.T. Carbon nanotubes for biomedical applications. IEEE Trans. Nanobioscience 2005, 4 (2), 180-195.
97. Yan, Y.; Chan-Park, M.B.; Zhang, Q. Advances in Carbon- Nanotube Assembly. Small, 2007, 3 (1), 24-42.
98. Liu, X.; Tao, H.; Yang, K.; Zhang, S.; Lee, S.T.; Liu, Z. Optimization of surface chemistry on single-walled carbon nanotubes for in vivo photothermal ablation of tumors. Biomaterials 2011, 32 (1), 144-151.
99. Chen, Z.; Pierre, D.; He, H.; Tan, S.; Pham-Huy, C.; Hong, H.; Huang, J. Adsorption behavior of epirubicin hydrochloride on carboxylated carbon nanotubes. Int. J. Pharmaceutics 2011, 405 (1- 2), 153-161.
100. Luo, G.; Long, J.; Zhang, B.; Liu, C.; Ji, S.; Xu, J.; Yu, X.; Ni, Q. Quantum dots in cancer therapy. Expert Opin. Drug Deliv. 2012, 9 (1), 47-58.
101. Biju, V.; Itoh, T.; Ishikawa, M. Delivering quantum dots to cells: bioconjugated quantum dots for targeted and nonspecific extracellular and intracellular imaging. Chem. Soc. Rev. 2010, 39, 3031-3056.
102. Bagalkot, V.; Zhang, L.; Nissenbaum, E.L.; Jon, S.; Kantoff, P.W.; Langer, R.; Farokhzad, O.C. Quantum Dot-Aptamer Conjugates for Synchronous Cancer Imaging, Therapy, and Sensing of Drug Delivery Based on Bi-Fluorescence Resonance Energy Transfer. Nano Lett. 2007, 7 (10), 3065-3070.
103. Gao, X.; Chung, L.W.K.; Shuming, N.S. Quantum Dots for in vivo Molecular and Cellular Imaging. Methods Mol. Bio. 2007, 374 (III), 135-145.
104. Li, Z.; Huang, P.; He, R.; Zhang, X.; Bao, C.; Ren, Q.; Cui, D. Aptamer-conjugated dendrimer-modified quantum dots for glioblastoma cells imaging. J. Phys. Conf. Ser. 2009, 188 (1), 012032.
105. Chen, C.; Peng, J.; Xia, H.S. Quantum dots-based immunofluorescence technology for the quantitative determination of HER2 expression in breast cancer. Biomaterials 2009, 30 (15), 2912-2918.
106. Ferry, D.R.; Traunecker, H.; Kerr, D.J. Clinical trials of Pglycoprotein reversal in solid tumors. Eur. J. Cancer 1996, 32A (6), 1070-1081.
107. Pepin, X.; Attali, L.; Domrault, C.; Gallet, S.; Metreau, J.M.; Reault; Cardot, P.J.; Imalalen, M.; Dubernet, C.; Soma, E.; Couvreur, P. On the use of ion-pair chromatography to elucidate doxorubicin release mechanism from polyalkylcyanoacrylate nanoparticles at the cellular level. J. Chromatogr. B. 1997, 702 (1- 2), 181-191.
108. Davis, M.E.; Chen, Z.G.; Shin, D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 2008, 7(9), 771-782.
109. Schluep, T.; Hwang, J.; Cheng, J.; Heidel, J.D.; Bartlett, D.W.; Hollister, B.; Davis, M.E. Preclinical efficacy of the camptothecinpolymer conjugate IT-101 in multiple cancer models. Clin. Cancer Res. 2006, 12, 1606-1614.
110. Northfelt, D.W.; Dezube, B.J.; Thommes, J.A.; Levine, R.; Von Roenn, J.H.; Dosik, G.M.; Rios, A.; Krown, S.E.; DuMond, C.; Mamelok, R.D. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J. Clin. Oncol. 1997, 15, 653-659.
111. Lee, K.S.; Chung, H.C.; Im, S.A.; Park, Y.H.; Kim, C.S.; Kim, S.B.; Rha, S.Y.; Lee, M.Y.; Ro, J. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res. Treat. 2008, 108, 241-250.
112. Nemunaitis, J.; Cunningham, C.; Senzer, N.; Gray, M.; Oldham, F.; Pippen, J.; Mennel, R.; Eisenfeld, A. Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors. Cancer Invest. 2005, 23, 671-676.
113. Lukianova-Hleb, E.Y.; Hanna, E.Y.; Hafner, J.H.; Lapotko, D.O. Tunable plasmonic nanobubbles for cell theranostics. Nanotechnology 2010, 21 (8), 085102.
114. Shubayev, V.I.; Pisanic, T.R.; Jin, S. Magnetic nanoparticles for theragnostics. Adv. Drug Deliver. Rev. 2009, 61 (6), 467-477.
115. Shim, M.S.; Kim, C.S.; Ahn, Y.C.; Chen, Z.; Kwon, Y.J. Combined multimodal optical imaging and targeted gene silencing using stimuli-transforming nanotheragnostics. J. Am. Chem. Soc. 2010, 132 (24), 8316-8324.
116. Rihova, B.; Riha, I. Immunological problems of polymer-bound drugs. Crit. Rev. Ther. Drug Carrier Syst. 1985, 1 (4), 311-374.
117. Duncan, R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2003, 2 (5), 347-360.
118. Wang, B.; Feng, W.Y.; Wang, T.C.; Jia, G.; Wang, M.; Shi, J.W.; Zhang, F.; Zhao, Y.L.; Chai, Z.F. Acute toxicity of nano- and micro-scale zinc powder in healthy adult mice. Toxicol Lett. 2006, 161 (2), 115-123.
119. Neerman, M.F.; Zhang, W.; Parrish, A.R.; Simanek, E.E. In vitro and in vivo evaluation of a melamine dendrimer as a vehicle for drug delivery.Int. J. Pharmaceutics 2004, 281 (1-2), 129-132.
120. Meerum Terwogt, J. M.; ten Bokkel Huinink, W.W.; Schellens, J.H.; Schot, M.; Mandjes, I.A.; Zurlo, M.G.; Rocchetti, M.; Rosing, H.; Koopman, F.J.; Beijnen, J.H. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anti-cancer Drug 2001, 12 (4), 315-323.
121. Canesi, L.; Ciacci, C.; Betti, M.; Fabbri, R.; Canonico, B.; Fantinati, A.; Marcomini, A.; Pojana, G. Immunotoxicity of carbon black nanoparticles to blue mussel hemocytes. Environ. Int. 2008, 34, 1114-1119.
122. Zhou, Y.; Yokel, R. The chemical species of aluminium influence its paracellular flux and uptake into Caco-2 cells, a model of gastrointestinal absorption. Toxicol. Sci. 2005, 87, 15-26.
123. Lam, C.W.; James, J.T.; McCluskey, R.; Hunter, R.L. Pulmonary toxicity of single wall carbon nanotubes in mice 7 and 90 days after intratracheal instillation. Toxicol. Sci. 2004, 77, 126-134.
124. Warheit, D.B.; Laurence, B.R.; Reed, K.L.; Roach, D.H.; Reynolds, G.A.; Webb, T.R. Comparative pulmonary toxicity assessment of single wall carbon nanotubes in rats. Toxicol. Sci. 2004, 77, 117-125.
125. Lovric, J.; Cho, S.J.; Winnik, F.M.; Maysinger, D. Unmodified cadmium telluride quantum dots induce reactive oxygen species formation leading to multiple organelle damage and cell death. Chem. Biol. 2005, 12, 1227-1234.
126. Sayes, C.M.; Gobin, A.M.; Ausman, K.D.; Mendez, J.; West, J.L.; Colvin, V.L. Nano-C60 cytotoxicity is due to lipid peroxidation. Biomaterials 2005, 26, 7587-7595.
127. Kim, J.S.; Yoon, T.J.; Yu, K. N.; Kim, B.G.; Park, S.J.; Kim, H.W.; Lee, K.H.; Park, S.B.; Lee, J.K.; Cho, M.H. Toxicity and tissue distribution of magnetic nanoparticles in mice. Toxicol. Sci. 2006, 89, 338-347.
128. Li, C.; Taneda, S.; Taya, K.; Watanabe, G.; Li, X.; Fujitani, Y.; Nakajima, T.; Suzuki, A.K. Effects of in utero exposure to nanoparticle-rich diesel exhaust on testicular function in immature male rats. Toxicol. Lett. 2009, 185, 1-8.
129. Kwon, J.; Hwang, S.; Jin, H.; Kim, D.S.; Minai-Tehrani, A.; Yoon, H.J.; Choi, M.; Yoon, T.J.; Han, D.Y.; Kang, Y.W.; Yoon, B.I.; Lee, J.K.; Cho, M.H. Body distribution of inhaled fluorescent magnetic nanoparticles in the mice. J. Occup. Health 2008, 50, 1-6.
130. Komatsu, T.; Tabata, M.; Kubo-Irie M.; Shimizu, T.; Suzuki, K.; Nihei, Y.; Takeda, K. The effects of nanoparticles on mouse testis Leydig cells in vitro. Toxicol. in vitro 2008, 22, 1825-1831.
131. Alexiou, C.; Arnold, W.; Klein, R.J.; Parak, F.G.; Hulin, P.; Bergemann, C.; Erhardt, W.; Wagenpfeil, S.; Lübbe, A.S. Locoregional cancer treatment with magnetic drug targeting. Cancer Res. 2000, 60, 6641-6648.
132. Braydich, S.L.; Hussain, S.M.; Schlager, J.; Hofmann, M.C. In vitro cytotoxicity of nanoparticles in mammalian germline stem cells. Toxicol. Sci. 2005, 88, 412-419.
133. Browning, L.M.; Lee, K.J.; Huang, T.; Nallathamby, P.D.; Lowman, J.E.; Xu, X.H. Random walk of single gold nanoparticles in zebrafish embryos leading to stochastic toxic effects on embryonic developments. Nanoscale 2009, 1, 138-152.
134. De, J.W.H.; Borm, P. Drug delivery and nanoparticles: applications and hazards. Int. J. Nanomed. 2008, 3, 133-149.
135. Chen, H.W.; Su, S.F.; Chien, C.T.; Lin, W.H.; Chen, J.J.W.; Pan, C.Y. Titanium dioxide nanoparticles induce emphysema-like lung injury in mice. FASEB J. 2006, 20 (130), 2393-2395.
136. Yen, H.J.; Hsu, S.H.; Tsai, C.L. Cytotoxicity and immunological response of gold and silver nanoparticles of different sizes. Small 2009, 5, 1553-1561.
137. Hussain, S.M.; Hess, K.L.; Gearhart, J.M.; Geiss, K.T.; Schlager, J.J. In vitro toxicity of nanoparticles in BRL 3A rat liver cells. Toxicol. in vitro 2005, 19 (7), 975-983.
138. Pisanic, T.R.; Blackwell, J.D.; Shubayev, V.I.; Fiñones, R.R.; Jin, S. Nanotoxicity of iron oxide nanoparticle internalization in growing neurons. Biomaterials 2007, 28, 2572-2581.
139. Kirpotin, D.B.; Drummond, D.C.; Shao, Y.; Shalaby, M.R.; Hong, K.; Nielsen, U.B.; Marks, J.D.; Benz, C.C.; Park, J.W. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006, 66 (13), 6732-6740.
140. Clift, M.J.; Rothen-Rutishauser, B.; Brown, D.M.; Duffin, R.; Donaldson, K.; Proudfoot, L.; Guy, K.; Stone, V. The impact of different nanoparticle surface chemistry and size on uptake and toxicity in a murine macrophage cell line. Toxicol. Appl. Pharmacol. 2008, 232 (3), 418-427.
141. Wang, S.; Kim, G.; Lee, Y.E.; Hah, H. J.; Ethirajan, M.; Pandey, R.K.; Kopelman, R. Multifunctional biodegradable polyacrylamide nanocarriers for cancer theranostics--a see and treat strategy. ACS Nano. 2012, 6 (8), 6843-6851.
142. Romberg, B.; Hennink, W.E.; Storm, G. Sheddable coatings for long-circulating nanoparticles. Pharm. Res. 2008, 25 (1), 55-71.
143. Dos Santos, N.; Allen, C.; Doppen, A.M.; Anantha, M.; Cox, K.A.; Gallagher, R.C.; Karlsson, G.; Edwards, K.; Kenner, G.; Samuels, L.; Webb, M.S.; Bally, M.B. Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding. Biochim. Biophys. Acta. 2007, 1768 (6), 1367-1377.
144. Karmali, P.P.; Simberg, D. Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems. Expert Opin. Drug Deliv. 2011, 8 (3), 343-357.
145. Ishida, T.; Atobe, K.; Wang, X.; Kiwada, H. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect ofdoxorubicin-encapsulation and high-dose first injection. J. Control. Release. 2006, 115 (3), 251-258.
146. Limbach, L.K.; Wick, P.; Manser, P.; Grass, R.N.; Bruinink, A.; Stark, W.J. Exposure of engineered nanoparticles to human lung epithelial cells: influence of chemical composition and catalytic activity on oxidative stress. Environ. Sci. Technol. 2007, 41 (11), 4158-4163.
147. Xia, T.; Kovochich, M.; Brant, J.; Hotze, M.; Sempf, J.; Oberley, T.; Sioutas, C.; Yeh, J.I.; Wiesner, M.R.; Nel, A.E. Comparison of the abilities of ambient and manufactured nanoparticles to induce cellular toxicity according to an oxidative stress paradigm. Nano Letters 2006, 6 (8), 1794-1797.
148. Akhter, S.; Ahmad, M.Z.; Ahmad, F.J.; Storm, G.; Kok, R.J. Gold nanoparticles in theranostic oncology: current state-of-the-art. Expert Opin. Drug Deliv. 2012, 9 (10), 1225-1243.
149. Desai, N. Challenges in development of nanoparticle-based therapeutics. AAPS J. 2012, 14 (2), 282-295.
150. Pasqualini, R.; Koivunen, E.; Kain, R.; Lahdenranta, J.; Sakamoto, M.; Stryhn, A.; Ashmun, R.A.; Shapiro, L.H.; Arap, W.; Ruoslahti, E. Amino peptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 2000, 60 (3), 722-727.
151. Oh, P.; Borgstrom, P.; Witkiewicz, H.; Li, Y.; Borgstrom, B.J.; Chrastina, A.; Iwata, K.; Zinn, K.R.; Baldwin, R.; Testa, J.E.; Schnitzer, J.E. Live dynamic imaging of caveolae pumping targeted antibody rapidly and speci fically across endothelium in the lung. Nat. Biotechnol. 2007, 25 (3), 327-337.
152. Borisch, B.; Semac, I.; Soltermann, A.; Palomba, C.; Hoessli, D.C. Anti-CD20 treat ments and the lymphocyte membrane: pathology for therapy. Verh. Dtsch. Ges. Pathol. 2001, 85, 161-166.
153. Cirstoiu-Hapca, A.; Bossy-Nobs, L.; Buchegger, F.; Gurny, R.; Delie, F. Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) couple d nanoparticles, Int. J. Pharmaceutics 2007, 331 (2), 190-196.
154. Graham, J.; Muhsin, M.; Kirkpatrick, P. Cetuximab. Nat. Rev. Drug Discov. 2004, 3 (7), 549-550.
155. Fonsatti, E. Nicolay, H.J. Altomonte, M. Covre, A. Maio, M. Targeting cancer vas culature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumors. Cardiovasc. Res. 2010, 86 (1), 12-19.
156. Singh, R.P.; Agarwal, R. Tumor angiogenesis: a potential target in cancer control by phytochemicals. Curr. Cancer Drug Target. 2003, 3 (3), 205-217.
157. Jubb, A.M.; Harris, A.L. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol. 2010, 11 (12), 1172-1183.
158. Ferguson, L.R.; Philpott, M. Cancer prevention by dietary bioactive components that target the immune response. Curr Cancer Drug Target. 2007, 7 (5), 459-464.
159. Ren, J.; Agata, N.; Chen, D.; Li, Y.; Yu, W.H.; Huang L.; Raina, D.; Chen, W.; Kharbanda, S.; Kufe, D. Human MUC1 carcinomaasso ciated protein confers resis- tance to genotoxic antic ancer agents. Cancer Cell 2004, 5 (2), 163-175.
160. Ladewig, K.; Xu, Z.P.; Lu, G.Q. Layered double hydroxide nanoparticles in gene and drug delivery. Expert Opin. Drug Deliv. 2009, 6 (9), 907-922.
161. Biao-xue, R.; Xi-guang, C.; Shuan-ying, Y.; Wei, L.; Zong-juan, M. EphA2-dependent molecular targeting therapy for malignant tumors. Curr. Cancer Drug Target. 2011, 11 (9), 1082-1097.
162. Wang, Y.; Sun, Y. Insulin-like growth factor receptor-1 as an anticancer target: blocking transformation andinducing apoptosis. Curr. Cancer Drug Target. 2002, 2 (3), 191-197.
163. Van der Veeken, J.; Oliveira, S.; Schiffelers, R.M.; Storm, G.; van Bergen En Henegouwen, P.M.; Roovers, R.C. Crosstalk between epidermal growth factor receptor-and insulin-like growth factor-1 receptorsignaling: implications for cancer therapy. Curr. Cancer Drug Target. 2009, 9 (6), 748-760.